Advertisement

Pharmacy World & Science

, Volume 30, Issue 1, pp 17–23 | Cite as

The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines

  • Rachel A. ElliottEmail author
  • Nick Barber
  • Sarah Clifford
  • Robert Horne
  • Elaine Hartley
Research Article

Abstract

Objective This “proof of concept” study aimed to assess the cost effectiveness of pharmacists giving advice via telephone, to patients receiving a new medicine for a chronic condition, in England. Methods The self-regulatory model (SRM) theory was used to guide development of our intervention and used in training pharmacists to adopt a patient-centred approach. Non-adherence to new medicines for chronic conditions develops rapidly so we developed a study intervention in which a pharmacist telephoned patients two weeks after they had started a new medicine for a chronic condition. Patients were included if they were 75 or older, or were suffering from stroke, cardiovascular disease, asthma, diabetes or rheumatoid arthritis, and were randomized into treatment or control arms. Main outcome measures were non-adherence and cost to the UK NHS, obtained via a questionnaire sent two months after starting therapy. Cost of the intervention was also included. Incremental cost effectiveness ratios (ICERs) were generated. Results Five hundred patients were recruited. At 4-week follow-up, non-adherence was significantly lower in the intervention group (9% vs 16%, p = 0.032). The number of patients reporting medicine-related problems was significantly lower in the intervention group compared to the control, (23% vs 34% p = 0.021). Mean total patient costs at 2-month follow-up (median, range) were intervention: £187.7 (40.6, 4.2–2484.3); control: £282.8 (42, 0–3804) (p < 0.0001). The intervention was dominant (less costly and more effective). If the decision maker is not willing to pay anything for one extra adherent patient, there is still a 90% probability that the intervention is cost effective. Conclusions These findings suggest that pharmacists can meet patients’ needs for information and advice on medicines, soon after starting treatment. While a larger trial is needed to confirm that the effect is real and sustained, these initial findings suggest the study intervention may be effective, at least in the short term, with a reduced overall cost to the health provider.

Keywords

Patient adherence Economic evaluation Randomised controlled trial Pharmacist England Telephone service 

Notes

Acknowledgements

We would like to thank the many who helped us: Intervention pharmacists: Helen Smurthwaite, Glen Savage. Expert panel: Imogen Savage, Mike Schachter, Colin Bradley, John Benson. Statistical advice: Colin Chalmers. Financial support This work was funded by the DHSC London Research & Development, Responsive Funding Programme. The expressed views in the publication are those of the authors and not necessarily those of the NHS or the Department of Health. Conflicts of interest The author have not reported any conflicts of interest.

References

  1. 1.
    Dartnell JGA, Anderson RP, Chohan V, Galbraith KJ, Lyon MEH, Nestor PJ et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996;164:659–62.PubMedGoogle Scholar
  2. 2.
    Psaty BM, Koepsell TD, Wagner EH, lo Gerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of B-Blockers. J Am Med Assoc 1990;263(12):1653–7.CrossRefGoogle Scholar
  3. 3.
    Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419–29.PubMedGoogle Scholar
  4. 4.
    Lau DT, Nau DP. Oral antihypoglycaemic medication nonadherence and subsequent hospitalization among individuals with Type 2 diabetes. Diabetes Care 2004;27:2149–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of Medication Adherence and Associated Health Care Costs in an Older Population with Type 2 Diabetes Mellitus: A Longitudinal Cohort Study. Clinical Therapeutics 2003;(11):2958–71.Google Scholar
  6. 6.
    Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006;333(7557):15–21.CrossRefGoogle Scholar
  7. 7.
    Lewis A. Noncompliance: A $100 billion problem. Remington Rep 1997;5:14–5.Google Scholar
  8. 8.
    Zuger A. The ‘other’ drug problem: forgetting to take them. The New York Times 1998 Jun 2.Google Scholar
  9. 9.
    Coambs RB, Jarry JL, Jensen P, Her MH, Porter J, Ferguson BS et al. Prescription non-compliance and inappropriate prescribing in Canada: causes, consequences and costs. Toronto, Canada: Health Canada Publications; 1998.Google Scholar
  10. 10.
    Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, Marco R. International variations in asthma treatment compliance. Eur Respir J 1999;14:288–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003;12:280–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005;39:508–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. J Lancet 1996;348:383–6.CrossRefGoogle Scholar
  14. 14.
    Campbell M, Fitzpatrick R, Haines A, Kinmonth A-L, Sandercock P, Spiegelhalter DJ. Framework for design and evaluation of complex interventions to improve health. Br Med J 2000;321:694–6.CrossRefGoogle Scholar
  15. 15.
    Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 2006;296(21):2563–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. Qual Saf Health Care 2004;13:172–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Horne R. Treatment perceptions and self regulation. In: Cameron D, Leventhal H eds., The self-regulation of health and illness behaviour.London: Routledge; 2003. p. 138–53, ISBN 0415297001.Google Scholar
  18. 18.
    Leventhal H, Cameron LD. Behavioral theories and the problem of compliance. Patient Educ Couns 1987;10:117–38.CrossRefGoogle Scholar
  19. 19.
    Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. The Cochrane Database of Systematic Reviews 2002;(Issue 2).Google Scholar
  20. 20.
    Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998;3(4):233–45.PubMedGoogle Scholar
  21. 21.
    Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost effectiveness acceptability curves. Health Econ 2001;10:779–87.PubMedCrossRefGoogle Scholar
  22. 22.
  23. 23.
    Netten A, Dennett J. Unit costs of community care. Kent: Personal Social Services Research Unit; 2005. Report No.: ISBN 1092671406.Google Scholar
  24. 24.
    Haynes RB, Yao X, Degani A, Kripalani S, Garg A, MacDonald HG. Interventions for enhancing medication adherence. The Cochrane Database of Systematic Reviews 20054(Art. No.: CD000011.pub2.).Google Scholar
  25. 25.
    NHS Business Services Authority Prescription Pricing Division. New Contractual Framework for Community Pharmacy: Payment for Advanced Services; Medication Use Reviews. http://www ppa org uk/ppa/contract_framework_for_community_pharmacy htm#medsusereview 2007 [cited 2007 Jan 12];.Google Scholar
  26. 26.
    Myers LB, Midence K. Methodological and conceptual issues in adherence. In: Myers LB, Midence K, (eds.), Adherence to treatment in medical conditions. Amsterdam: Harwood Academic Publishers; 1998. ISBN 9057022648.Google Scholar
  27. 27.
    Milgrom H, Bender BG, Ackerson LM, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Bender BG, Milgrom H, Rand C, Ackerson LM. Psychological factors associated with medication non-adherence in asthmatic children. J Asthma 1998;35:347–53.PubMedGoogle Scholar
  29. 29.
    Bender BG, Wamboldt FS, O’Connor SL, Rand C, Szefler S, Milgrom H et al. Measurement of children’s asthma medication adherence by self-report, mother report, canister weight, and Doser CT. Ann Allergy Asthma Immunol 2000;85:416–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Nichol MB, Venturini F, Sung JCY. A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother 1999;33:531–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Choo PW, Rand CS, Inui TS, Lee M, Cain E, Cordeiro-Breault M et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Matthews DR, Stratton IM, Aldington SJ, Homan RR, Kohner EM. UKPDS 69 Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. Arch Ophthal 2004;122:1631–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Simpson SH, Johnson JA, Biggs C, Biggs RS, Kuntz A, Semchuk W et al. Practice-based research: Lessons from community pharmacist participants. Pharmacotherapy 2001;21(6):731–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. Int J Pharm Pract 2000;8:165–75.Google Scholar
  35. 35.
    Goodyer LI, Miskelly F, Milligan P. Does encouraging good compliance improve patients’ clinical condition in heart failure? Br J Clin Pharmacol 1995;49:173–6.Google Scholar
  36. 36.
    Department of Health. NHS R & D Strategic Review Primary Care Working Group: Report of the Pharmacy subgroup. https://www dh gov uk/assetRoot/04/02/09/41/04020941 pdf 1999 [cited 2006 Jul 10].Google Scholar
  37. 37.
    Department of Health. Pharmacy in the future: Implementing the NHS Plan. http://195 33 102 76/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4005917&chk=/4q1tW 2000 [cited 2006 Jul 10].Google Scholar
  38. 38.
    Department of Health. A vision for pharmacy in the new NHS. http://www dh gov uk/Consultations/ClosedConsultations/ClosedConsultationsArticle/fs/en?CONTENT_ID=4068353&chk=Y2fMuy 2003 July [cited 2006 Jul 10].Google Scholar
  39. 39.
    Department of Health. National Service Framework for Coronary Heart Disease. www dh gov uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en 2000 [cited 2006 Jul 10].Google Scholar
  40. 40.
    Department of Health. National Service Framework for Older People. www dh gov uk/PolicyAndGuidance/HealthAndSocialCareTopics/olderpeople/fs/en 2001 [cited 2006 Jul 10].Google Scholar
  41. 41.
    Department of Health. National Service Framework for Diabetes. www dh gov uk/PolicyAndGuidance/HealthAndSocialCareTopics/diabetes/fs/en 2003 [cited 2006 Jul 10].Google Scholar
  42. 42.
    Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47(6):555–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Rachel A. Elliott
    • 1
    Email author
  • Nick Barber
    • 2
  • Sarah Clifford
    • 2
  • Robert Horne
    • 2
  • Elaine Hartley
    • 3
  1. 1.School of Pharmacy and Pharmaceutical SciencesUniversity of ManchesterManchesterUK
  2. 2.Centre for Behavioural MedicineThe School of PharmacyLondonUK
  3. 3.Alliance PharmacyFalthamUK

Personalised recommendations